Researchers at Columbia University have described how excess fibronectin, a protein that helps support tissue structure, damages the brain's blood vessels in people carrying the APOE ε4 gene variant. The work, published in Nature Aging, builds on an earlier finding that a rare mutation in the fibronectin (FN1) gene appeared to protect some APOE ε4 carriers from Alzheimer's. The new study tries to explain why too much fibronectin is harmful in the first place.
The team, led by corresponding author Caghan Kizil, combined analyses of human brain tissue and cerebrospinal fluid with stem-cell models, three-dimensional blood vessel cultures, and experiments in zebrafish and mice. In mice carrying human APOE ε4, researchers measured nearly twice as much brain fibronectin as in mice carrying APOE ε3, and the blood-brain barrier appeared leaky. In one key experiment, raising fibronectin specifically in astrocytes, the support cells that help maintain the barrier, was enough to make it more permeable, while reducing fibronectin improved barrier function.
The researchers traced a mechanism in which excess fibronectin triggers abnormal signaling through integrins and the enzyme focal adhesion kinase. This disrupts a network of growth factors, VEGF, HBEGF, and IGF1, that normally help astrocytes and blood vessel cells coordinate to keep the barrier intact. Signs of similar disturbances appeared in human Alzheimer's tissue, and elevated fibronectin was associated with inflammation in astrocytes.
For researchers, this gives a more concrete target than a genetic association alone. The authors suggest three broad approaches: preventing harmful fibronectin buildup around blood vessels, blocking the abnormal signals it triggers, or restoring the growth factor signaling that protects the barrier. The authors also note that fibronectin does essential work in healing and tissue support, so any therapy would need to act on its harmful accumulation without disrupting those functions. The researchers also suggest the mechanism could help determine when interventions would be most effective and how to measure whether they are working.
Because APOE ε4 is the strongest common genetic risk factor for Alzheimer's, and roughly one in five people carries at least one copy, understanding the pathway matters for a large population. The authors describe these potential therapies as experimental, so the work is a step toward treatment ideas rather than a treatment itself.